Notice: Essential maintenance to our website is being carried out this weekend 22nd-23rd January so you may experience some disruption in accessing the site.
This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: hypercholesterolaemia

November 2021

HEART UK – Hypercholesterolaemia: familial or not?

Andreas Tridimas

Abstract

Familial hypercholesterolaemia or not? The importance of considering polygenic hypercholesterolaemia in those with no monogenic cause for familial hypercholesterolaemia (FH), was outlined by Professor Steve Humphries (UCL Institute of Cardiovascular Science, London).1 By looking for the presence of specific high low-density lipoprotein cholesterol (LDL-C), single nucleotide polymorphisms (SNPs) and combining these to generate a SNP-score, those with the most variants can be identified. Professor Steve Humphries Individuals who are in the top five deciles of the SNP-score are highly likely to have a polygenic explanation for their high LDL-C

| Full text
Statins and myalgia: fact or fiction?

October 2015 Br J Cardiol 2015;22:127–9 doi:10.5837/bjc.2015.033 Online First

Statins and myalgia: fact or fiction?

Peter Sever

Abstract

(more…)

| Full text
Towards personalised medicine: HEART UK 28th Annual Conference

September 2014 Br J Cardiol 2014;21:104

Towards personalised medicine: HEART UK 28th Annual Conference

BJCardio Staff and others

Abstract

FH: improving detection in primary care The launch of the NICE (National Institute of Health and Care Excellence) guidelines for familial hypercholesterolaemia (FH) heralded great optimism for improving detection rates in primary care.1 Even with new research showing that FH is more common than previously thought,2  still around 80% of patients are not recognised. Novel detection approaches are clearly needed. Professor Nadeem Qureshi (University of Nottingham) presented preliminary findings from six GP centres taking part in FAMCHOL (Feasibility of Improving Identification of Familial Hypercholesterolaemia in General Practice: Intervention

| Full text

November 2009 Br J Cardiol 2009;16:295–8

Colesevelam – where does it fit into our clinical practice?

Devaki Nair

Abstract

Introduction Bile acid sequestrants (BAS) were the first class of lipid-lowering drug to be developed for reducing blood cholesterol levels.1 Now, after their introduction 30 years ago, BAS still continue to command a position in the treatment of hyperlipidaemia.2 How do BAS work? Figure 1. Mode of action of bile acid sequestrants BAS bind to negatively charged bile acids in the intestine and impede their absorption (figure 1). This process depletes the bile acid pool and disrupts the enterohepatic circulation of bile acids, thus, increasing the synthesis of bile acids. Cholesterol is, therefore, diverted to bile acid synthesis, thereby reduc

| Full text

May 2006 Br J Cardiol 2006;13:196-202

Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK

Andrew Davies, John Hutton, John O'donnell, Sarah Kingslake

Abstract

No content available

| Full text

January 2006 Br J Cardiol 2006;13:72-6

Achieving lipid goals in real life: the DISCOVERY-UK study

Alan Middleton, Ahmet Fuat

Abstract

No content available

| Full text

July 2004 Br J Cardiol 2004;11:292-9

Hypercholesterolaemia and its potential role in the presentation and exacerbation of hypertension

Andrei C Sposito, Jose Augusto S Barreto-Filho

Abstract

No content available

| Full text

March 2004 Br J Cardiol 2004;11:148-55

Efficacy and safety of fluvastatin ER 80 mg compared with fluvastatin IR 40 mg in the treatment of primary hypercholesterolaemia

William Insull Jr, Adrian D Marais, Ronnie Aronson, Sheryl Manfreda, and the Fluvastatin Study Group

Abstract

No content available

| Full text

September 2002 Br J Cardiol 2002;9:469-75

Extended-release fluvastatin 80 mg shows greater efficacy, with comparable tolerability, versus immediate-release fluvastatin 40 mg for once daily treatment of primary hypercholesterolaemia

Donald B Hunninghake, Michael Davidson, Howard R Knapp, Helmut G Schrott, Sheryl Manfreda, and the Fluvastatin Study Group

Abstract

No content available

| Full text

September 2002 Br J Cardiol 2002;9:460-8

The role of orlistat in the treatment of obese patients with mild to moderate hypercholesterolaemia: consequences for coronary risk

Iain Broom, Elixabeth Hughes, Paul Dodson, John Reckless, on behalf of the Orlistat UK Study Group

Abstract

No content available

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now